Precision Neuroscience
Precision Neuroscience, founded in New York, USA in 2021, develops brain-computer interface (BCI) technology aimed at treating neurological conditions such as motor paralysis and neurodegenerative diseases.
Position in SVTR
Snapshot 2026-10-24- Startup SignalsTop 10%↓7
- Life Sciences#4of 247–
- Healthcare Services#3of 86–
- Medtech Device#1of 41–
- BCI#1of 18–
About
Precision Neuroscience, founded in New York, USA in 2021, develops brain-computer interface (BCI) technology aimed at treating neurological conditions such as motor paralysis and neurodegenerative diseases. Its device, called the Layer 7 Cortical Interface, sits on top of the brain rather than penetrating brain tissue, representing a middle ground between invasive and non-invasive BCI approaches, and contrasts with devices from companies such as Blackrock Neurotech, Inbrain Neuroelectronics SL, Neuralink, and Paradromics that are implanted within brain tissue.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 12
Investor· 10
Founders / team· 4
Funding history
- 2026-09-24Series D$250M
Investors · Pershing Square, Ackman Oxman Institute, Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset, Korea Investment Partners, Hitachi Ventures, JSL HealthSource · mobihealthnews.com ↗
- 2024-12-16Series C$102M
Investors · General Equity Holdings, Steadview Capital, Duquesne Family Office, B CapitalSource · SVTR Weekly #084
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Precision Neuroscience
building the next generation of brain-computer interfaces (BCIs) with a minimally invasive, high-density implant
Series D+ · $430M · 2026-09
$430M
United States
BusinessLatest roundTotal raisedDate- Cityblock Health
A value-based care platform providing primary care, behavioral health, chronic disease management and social services to high-need Medicaid and Medicare populations in the United States
Series D+ · $1.0B · 2026-08
$1.0B - Abridge
Provides software that lets AI listen to doctor-patient conversations and automatically generate medical records and billing codes
Series D+ · $800M · 2025-06 · Valuation $5.3B
$800MValuation $5.3B - Suki
Ambient AI assistant for healthcare (clinical documentation, coding and administrative automation)
Series D+ · $250M · 2026-10
$250M
China
BusinessLatest roundTotal raisedDate- StairMed
Developer of implantable brain-computer interface systems
Strategic · $153M · 2026-03
$153M - 格式塔科技
Ultrasound brain-computer interface for whole-brain read/write, treating chronic pain, stroke rehabilitation, PTSD and other neurological conditions
Angel · $80M · 2026-07
$80M - BCI-Sonics
Non-invasive AI ultrasound brain-computer interface (transcranial focused ultrasound neuromodulation + multimodal brain reading and AI neural decoding)
Series A · $42M · 2026-09
$42M
Europe
BusinessLatest roundTotal raisedDate- Tandem Health
AI clinical assistant for European healthcare providers: pre-visit summaries, real-time consultation transcription, and automatic post-visit generation of medical records and diagnostic codes
Series B · $160M · 2026-09
$160M - Corti
Uses AI to assess patients in collaboration with clinicians
Series B · $60M · 2023-09
$60M - Voize
AI voice documentation assistant for frontline nursing that generates standardized nursing records automatically
Series A · $59M · 2025-11
$59M
Other / unspecified
BusinessLatest roundTotal raisedDate- Heidi Health
AI ambient documentation and clinical agent for clinicians (AI Care Partner)
Series C · $437M · 2026-09 · Valuation $900M
$437MValuation $900M - Craif
Urine microRNA plus AI early cancer detection service (miSignal) and software medical device development for pancreatic cancer diagnosis
Series D+ · $88M · 2026-08
$88M - Even Healthcare
Health subscription membership for individuals and businesses (unlimited consultations, free testing), with a company-operated network of hospitals and clinics and accompanying health insurance.
Series B · $120M · 2026-10 · Valuation $300M
$120MValuation $300M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 7 at a nearby stage · 36 in NYC Metro
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 3 at a nearby stage · 31 in NYC Metro
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 10 at a nearby stage · 22 in NYC Metro
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 6 at a nearby stage · 20 in NYC Metro
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 8 at a nearby stage · 15 in NYC Metro
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 5 at a nearby stage · 15 in NYC Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.